<p>Effect of rivaroxaban on DNA damage in an ischemia-reperfusion model: Evaluation of 8‑OHdG levels</p>

Sayarer,Ceren; Erdal,Abidin Cenk; Gençpinar,Tuğra; Doruk,Özlem Gürsoy; Küme,Tuncay

doi:10.3892/etm.2026.13069

March-2026 Volume 31 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2026 Volume 31 Issue 3

Full Size Image

Article Open Access

Effect of rivaroxaban on DNA damage in an ischemia-reperfusion model: Evaluation of 8‑OHdG levels

Authors:
- Ceren Sayarer
- Abidin Cenk Erdal
- Tuğra Gençpinar
- Özlem Gürsoy Doruk
- Tuncay Küme
View Affiliations / Copyright

Affiliations: Department of Cardiovascular Surgery, Dokuz Eylül University, Izmir 35340, Turkey, Department of Medical Biochemistry, Dokuz Eylül University, Izmir 35340, Turkey

Copyright: © Sayarer et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 74
|
Published online on: January 21, 2026

https://doi.org/10.3892/etm.2026.13069
Expand metrics +

Abstract

Ischemia‑reperfusion (I/R) injury is a notable cause of tissue damage, particularly in patients with peripheral artery disease. Rivaroxaban is a novel oral anticoagulant that can reduce cardiovascular events. However, its potential antioxidant properties remain poorly understood. Therefore, the present study aimed to investigate the effect of rivaroxaban on oxidative DNA injury in a rat model of I/R injury by measuring 8‑hydroxy‑2'‑deoxyguanosine (8‑OHdG) levels, a key biomarker of oxidative DNA injury. A total of 21 female Wistar albino rats were randomly divided into three groups, namely the sham, control (I/R) and rivaroxaban treatment (3 mg/kg/day) groups. Following treatment for 10 days, hind limb ischemia was induced in rats for 1 h, followed by reperfusion for 2 h. Subsequently, blood and skeletal muscle samples were collected and analyzed for oxidative stress markers, including 8‑OHdG, glutathione (GSH), oxidized GSH and malondialdehyde (MDA), using ELISA and high‑performance liquid chromatography. The results demonstrated that compared with those in the sham group, rats in the control group exhibited significantly elevated 8‑OHdG, GSSG and MDA levels, coupled with decreased GSH levels. By contrast, treatment with rivaroxaban notably reversed the elevated 8‑OHdG and MDA levels whilst restoring GSH levels compared with those in the control group, indicating an improved oxidative status. Overall, these findings suggested that in addition to its established anticoagulant properties, rivaroxaban can also protect against I/R‑induced oxidative DNA injury.

View Figures

View References

1	Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA and Criqui MH: Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet. 382:1329–1340. 2013.PubMed/NCBI View Article : Google Scholar
2	Sigvant B, Hasvold P, Kragsterman B, Falkenberg M, Johansson S, Thuresson M and Nordanstig J: Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study. J Vasc Surg. 66:507–514.e1. 2017.PubMed/NCBI View Article : Google Scholar
3	Blaisdell FW: The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: A review. Cardiovasc Surg. 10:620–630. 2002.PubMed/NCBI View Article : Google Scholar
4	Hess CN, Debus ES, Nehler MR, Anand SS, Patel MR, Szarek M, Capell WH, Hsia J, Beckman JA, Brodmann M, et al: Reduction in acute limb ıschemia with rivaroxaban versus placebo in peripheral artery disease after lower extremity revascularization: Insights from VOYAGER PAD. Circulation. 144:1831–1841. 2021.PubMed/NCBI View Article : Google Scholar
5	Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, et al: Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 199:83–91. 2018.PubMed/NCBI View Article : Google Scholar
6	Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, et al: 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 135:e686–e725. 2017.PubMed/NCBI View Article : Google Scholar
7	Qin Z and Xu Y: Dexmedetomidine alleviates brain ıschemia/reperfusion ınjury by regulating metastasis-associated lung adenocarcinoma transcript 1/MicroRNA-140-5p/nuclear factor erythroid-derived 2-like 2 axis. Protein Pept Lett. 31:116–127. 2024.PubMed/NCBI View Article : Google Scholar
8	Bagheri Y, Ahmadian E, Hejazian SM, Raeesi M, Zununi Vahed S and Ardalan M: The effect of fingolimod on renal ıschemia/reperfusion ınjury in a rat model. Curr Mol Pharmacol: Oct 23, 2024 (Epub ahead of print).
9	Perrelli MG, Pagliaro P and Penna C: Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. World J Cardiol. 3:186–200. 2011.PubMed/NCBI View Article : Google Scholar
10	Di Minno A, Turnu L, Porro B, Squellerio I, Cavalca V, Tremoli E and Di Minno MND: 8-Hydroxy-2-deoxyguanosine levels and cardiovascular disease: a systematic review and meta-analysis of the literature. Antioxid Redox Signal. 24:548–555. 2016.PubMed/NCBI View Article : Google Scholar
11	Ishibashi Y, Matsui T, Fukami K, Ueda S, Okuda S and Yamagishi S: Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 system. Thromb Res. 135:770–773. 2015.PubMed/NCBI View Article : Google Scholar
12	Costa OS, Kohn CG, Kuderer NM, Lyman GH, Bunz TJ and Coleman CI: Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism. Blood Adv. 4:4045–4051. 2020.PubMed/NCBI View Article : Google Scholar
13	Lee SG, Yim J, Lim Y and Kim JH: Validation of a liquid chromatography tandem mass spectrometry method to measure oxidized and reduced forms of glutathione in whole blood and verification in a mouse model as an indicator of oxidative stress. J Chromatogr B Analyt Technol Biomed Life Sci. 1019:45–50. 2016.PubMed/NCBI View Article : Google Scholar
14	Dalle-Donne I, Rossi R, Colombo R, Giustarini D and Milzani A: Biomarkers of oxidative damage in human disease. Clin Chem. 52:601–623. 2006.PubMed/NCBI View Article : Google Scholar
15	Guide for the Care and Use of Laboratory Animals. National Academies Press, Washington, DC, 2011.
16	Rosero O, Németh K, Turóczi Z, Fülöp A, Garbaisz D, Győrffy A, Szuák A, Dorogi B, Kiss M, Nemeskéri Á, et al: Collateral circulation of the rat lower limb and its significance in ischemia-reperfusion studies. Surg Today. 44:2345–2353. 2014.PubMed/NCBI View Article : Google Scholar
17	Durmaz S, Kurtoğlu T, Rahman ÖF, Tataroğlu C, Yılmaz M, Barbarus E and Erkan MH: Direct oral anticoagulant agents attenuate temporary aortic occlusion-induced renal oxidative and inflammatory responses in rats. Turk Gogus Kalp Damar Cerrahisi Derg. 30:184–191. 2022.PubMed/NCBI View Article : Google Scholar
18	Heitzer M, Winnand P, Bock A, Ooms M, Katz MS, Kniha K, Grottke O, Hölzle F and Modabber A: Evaluation of the hemostatic effect of an ınnovative tissue adhesive during extraction therapy under rivaroxaban in a rodent model. J Funct Biomater. 14(333)2023.PubMed/NCBI View Article : Google Scholar
19	Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA and Fowkes FGR: TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 45 (Suppl 1):S5–S67. 2007.PubMed/NCBI View Article : Google Scholar
20	Wu MY, Yiang GT, Liao WT, Tsai AP, Cheng YL, Cheng PW, Li CY and Li CJ: Current mechanistic concepts in ıschemia and reperfusion ınjury. Cell Physiol Biochem. 46:1650–1667. 2018.PubMed/NCBI View Article : Google Scholar
21	Bukowska A, Zacharias I, Weinert S, Skopp K, Hartmann C, Huth C and Goette A: Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. Eur J Pharmacol. 718:114–123. 2013.PubMed/NCBI View Article : Google Scholar
22	Chen Y, Fan C, Wang J and Jiang M: Rivaroxaban combined with atorvastatin ınhibits acute pulmonary embolism by promoting the expression of NRF2/NQO1. Cardiovasc Drugs Ther. 38:1271–1287. 2024.PubMed/NCBI View Article : Google Scholar
23	Atzemian N, Kareli D, Ragia G and Manolopoulos VG: Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: A comprehensive review. Front Pharmacol. 14(1244098)2023.PubMed/NCBI View Article : Google Scholar
24	Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, et al: Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 382:1994–2004. 2020.PubMed/NCBI View Article : Google Scholar
25	Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al: Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 377:1319–1330. 2017.PubMed/NCBI View Article : Google Scholar
26	Bozkurt AK: National Guideline for Peripheral Arterial and Venous Diseases. Turkish Society of Cardiovascular Surgery, Turkish Society of Vascular and Endovascular Surgery, Turkish Phlebology Society; 2021. Available at: https://www.tkdcd.org/uploads/content/pdf/kilavuzlar/Ulusal_Tedavi_Kilavuzu_2021.pdf.